Chronic Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3495
Buy Report Download FREE Resources

Published: August 09, 2024 Report Code: GDHC169CL-ST

Select Item

Chronic Urticaria Marketed and Pipeline Drugs Report Overview

Chronic Urticaria (CU) is characterized by urticaria persisting continuously or intermittently for at least six weeks. CU includes chronic inducible urticaria (CIndU), also known as physical urticaria, and CSU. CSU is a mast cell-driven disorder characterized by the recurrent appearance of hives and/or angioedema persisting for more than six weeks.

Key Mechanisms of Action (Marketed) ·       Receptor Antagonists

·       Receptor Agonists

·       Enzyme Inhibitors

·       Biological Factor Inhibitors

·       Protein and Peptide Inhibitors
Key Molecule Types (Marketed) ·       Small Molecules

·       Biologics
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

The chronic urticaria marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for chronic urticaria.

The report also provides actionable insights into the clinical and commercial landscapes of AH, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.

Key Mechanisms of Action (Pipeline) ·       Enzyme Inhibitors

·       Receptor Antagonists

·       Receptor Inhibitors

·       Biological Factor Inhibitors

·       Protein and Peptide Inhibitors
Key Molecule Types (Pipeline) ·       Small Molecules

·       Biologics
Top Sponsors (Marketed and Pipeline Drugs) ·       Novartis AG

·       Celldex Therapeutics Inc.

·       Taiho Pharmaceutical Co Ltd.

·       Shiraz University of Medical Sciences

·       Sanofi
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Chronic Urticaria Marketed Drugs Segmentation by Mechanisms of Action

Most of the marketed drugs for CU are receptor antagonists in 2024. They are followed by receptor agonists, enzyme inhibitors, biological factor inhibitors, protein and peptide inhibitors, and others.

Chronic Urticaria Marketed Drugs Analysis by Mechanisms of Action, 2024 (%)

Chronic Urticaria Marketed Drugs Analysis by Mechanisms of Action, 2024 (%)

Buy the Full Report to Know More about the MoA of Chronic Urticaria Marketed Drugs

Download a Free Report Sample

Chronic Urticaria Marketed Drugs Segmentation by Molecule Types

In 2024, the leading molecule type for chronic urticaria marketed drugs is small molecules, followed by biologics.

Chronic Urticaria Marketed Drugs Analysis by Molecule Types, 2024 (%)

Chronic Urticaria Marketed Drugs Analysis by Molecule Types, 2024 (%)

Buy the Full Report to Know More about the Molecule Types of Chronic Urticaria Marketed Drugs

Download a Free Report Sample

Chronic Urticaria Pipeline Drugs Market Segmentation by Mechanisms of Action

The key MoA of the drugs in the chronic urticaria pipeline includes enzyme inhibitors, receptor antagonists, receptor inhibitors, biological factor inhibitors, protein and peptide inhibitors, and others. Most CU pipeline assets are enzyme inhibitors in 2024.

Chronic Urticaria Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)

Chronic Urticaria Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)

Buy the Full Report to Know More about the MoA of Chronic Urticaria Pipeline Drugs

Download a Free Report Sample

Chronic Urticaria Pipeline Drugs Market Segmentation by Molecule Types

In 2024, the leading molecule type for chronic urticaria pipeline drugs is biologics, followed by small molecules.

Chronic Urticaria Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)

Chronic Urticaria Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)

Buy the Full Report to Know More about the Molecule Types of Chronic Urticaria Pipeline Drugs

Download a Free Report Sample

Chronic Urticaria Marketed and Pipeline Drugs Market – Competitive Landscape

A few of the top sponsors in the chronic urticaria marketed and pipeline drugs market are Novartis AG, Celldex Therapeutics Inc., Taiho Pharmaceutical Co Ltd., Shiraz University of Medical Sciences, and Sanofi, among others. Novartis has conducted the highest number of total trials in CU in 2024.

Chronic Urticaria Marketed and Pipeline Drugs Market Analysis by Sponsors, 2024 (%)

Chronic Urticaria Marketed and Pipeline Drugs Market Analysis by Sponsors, 2024 (%)

Buy the Full Report for More Sponsor Insights into the Chronic Urticaria Marketed and Pipeline Drugs Market
Download a Free Report Sample

Segments Covered in the Report

Chronic Urticaria Marketed Drugs Mechanisms of Action Outlook (2024)

  • Receptor Antagonists
  • Receptor Agonists
  • Enzyme Inhibitors
  • Biological Factor Inhibitors
  • Protein and Peptide Inhibitors

Chronic Urticaria Marketed Drugs Molecule Types Outlook (2024)

  • Small Molecules
  • Biologics

Chronic Urticaria Pipeline Drugs Mechanisms of Action Outlook (2024)

  • Enzyme Inhibitors
  • Receptor Antagonists
  • Receptor Inhibitors
  • Biological Factor Inhibitors
  • Protein and Peptide Inhibitors

Chronic Urticaria Pipeline Drugs Molecule Types Outlook (2024)

  • Small Molecule
  • Biologic

Scope

The key components of the report include:

  • Disease Landscape

  • Disease Overview

  • Epidemiology Overview

  • Treatment Overview

  • Marketed Products Assessment

  • Breakdown by Mechanism of Action, Route of Administration

  • Product Profiles with Sales Forecast

  • Pricing and Reimbursement Assessment

  • Annual Therapy Cost

  • Time to Pricing and Time to Reimbursement

  • Pipeline Assessment

  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

  • Product Profiles with Sales Forecast

  • Late-to-mid-stage Pipeline Drugs

  • Phase Transition Success Rate and Likelihood of Approval

  • Clinical Trials Assessment

  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

  • Enrolment Analytics, Site Analytics, Feasibility Analysis

  • Deals Landscape

  • Mergers, Acquisitions, and Strategic Alliances by Region

  • Overview of Recent Deals

  • Commercial Assessment

  • Key Market Players

  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the chronic urticaria market.

  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global chronic urticaria market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Molecule Type

4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

5.1 Annual Cost of Therapy

5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Mid-to-late-stage Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Mechanism of Action

6.4 Overview by Molecule Type

6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Overview of Trials by Geography

7.7 Single-Country and Multinational Trials by Region

7.8 Top 20 Sponsors with Breakdown by Phase

7.9 Top 20 Sponsors with Breakdown by Status

7.10 Overview by Endpoint Status

7.11 Overview by Race and Ethnicity

7.12 Enrollment Data

7.13 Top 20 countries for Trial Sites

7.14 Top 20 Sites Globally

7.15 Feasibility Analysis – Geographic Overview

7.16 Feasibility Analysis – Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

11.1 Methodology

11.2 Methodology – Sales Forecast

11.3 Methodology – Pricing and Reimbursement

11.4 Methodology – PTSR and LoA Analysis

11.5 About the Authors

11.6 Contact Us

11.7 Disclaimer

Frequently asked questions

Chronic Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

Most Popular
$6,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Chronic Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Chronic Urticaria Or Hives reports
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, August 2026
$2,950 | September 2026
Pharmaceuticals
New
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive…
$3,495 | September 2026
Pharmaceuticals
New
Hodgkin Lymphoma: Epidemiology Report and Forecast
$9,995 | September 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live Chronic Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more